ABSTRACT : Adult community-acquired pneumonia (CAP) is a common cause of morbidity and mortality which is managed by different disciplines in a heterogeneous fashion. Development of consensus guidelines to standardize these wide variations in care has become a prime objective. The Lebanese Society of Infectious Diseases and Clinical Microbiology (LSIDCM) convened to set Lebanese national guidelines for the management of CAP since it is a major and a prevalent disease affecting the Lebanese population. These guidelines, besides being helpful in direct clinical practice, play a major role in establishing stewardship programs in hospitals in an effort to contain antimicrobial resistance on the national level. These guidelines are intended for primary care practitioners and emergency medicine phy-sicians. They constitute an appropriate starting point for specialists' consultation being based on the available local epidemiological and resistance data. This document includes the following: 1/ Rationale and scope of the guidelines; 2/ Microbiology of CAP based on Lebanese data; 3/ Clinical presentation and diagnostic workup of CAP; 4/ Management and prevention strategies based on the IDSA/ATS Consensus Guidelines, 2007, and the ESCMID Guidelines, 2011, and tailored to the microbiological data in Lebanon; 5/ Comparison to regional guidelines. The recommendations made in this document were graded based on the strength of the evidence as in the 2007 IDSA/ATS Consensus Guidelines. Hopefully, these guidelines will be an important step towards standardization of CAP care in Lebanon and set the agenda for further research in this area.
Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Management of Adult
Lower Respiratory Tract Infections (LRTI) [10] [11] , taking into consideration local microbiological data. Despite the fact that there is no registry for antibiotic resistance in Lebanon, the current recommendations were supported from available articles and reports that are published in the literature.
Due to the strong potential of fluoroquinolones to induce resistance and pass it on to other classes of antibiotics [12] and their high rate of resistance in Enterobacteriaceae in Lebanon [3] the LSIDCM members have decided to use them as a second choice except in indications where they are irreplaceable. The recommendations made in this document were graded based on the strength of the evidence as high-level (Level I), moderate-level (Level II), and low-level (Level III) evidence. It was adopted from the IDSA/ATS guidelines ( Table I) .
Scope of these Guidelines
In this article, recommendations are restricted to community-acquired pneumonia in adults in Lebanon.
MATERIALS AND METHODS

Definition of community-acquired pneumonia (CAP)
Pneumonia is an acute infection of the pulmonary parenchyma that is associated with symptom(s) of acute infection, accompanied by the presence of an acute infiltrate on a chest radiograph and/or auscultatory findings consistent with pneumonia (such as altered breath sounds and/or localized rales). CAP is a pneumonia that occurs in a patient not hospitalized or residing in a long-term care facility for more than 14 days before onset of symptoms. [9] .
However, it is very important to differentiate between pneumonia and other upper airway infection since their management differs [10] [11] .
Diagnosis of CAP
An acute febrile illness with cough and at least one new focal chest sign for four days or dyspnea/tachypnea without other obvious cause, supported by a shadow on chest radiograph is a diagnosis. In the elderly, the clinical symptoms might be very subtle [10] [11] . This illness occurs in patients not hospitalized or residing in a long-term care facility for more than 14 days before onset of symptoms [9] .
Microbiological considerations
The microbiological etiology of CAP has been described from a compendium of data in different studies in the UK, Europe and North America and Saudi Arabia [13] [14] [15] .
In one prospective study of 507 patients treated in an ambulatory setting in Canada, the most commonly identified microorganisms were Mycoplasma pneumoniae (17%), Chlamydia pneumoniae (14%), Streptococcus pneumoniae (6%), and Haemophilus influenzae (5%) [13] Despite considerable effort, an etiologic diagnosis could not be determined in (52%) of cases. In a prospective study from Spain that included 2521 ward patients with CAP, the most commonly identified organisms were Streptococcus pneumoniae (18%), respiratory viruses (5%), Legionella pneumophila (4%), and Haemophilus influenzae (2%) [14] . An etiology could not be determined in 59% of cases. In the same study from Spain, among 488 patients admitted to the intensive care unit, the most commonly identified organisms were Streptococcus pneumoniae (23%), Legionella pneumophila (4%), Pseudomonas aeruginosa (3%), Chlamydia pneumoniae (2%), and Haemophilus influenzae (2%) [14] . No pathogen was identified in (47%) of patients.
A review by the ESCMID group in 2011 found out that there has been no major change in causative pathogens for lower respiratory tract infection (LRTI). More information is now available about the frequency of polymicrobial infections including viral infections [10] [11] . On the other hand, Panton-Valentine leucocidin (PVL)-producing Staphylococcus aureus has emerged as a new cause, often of severe CAP, but currently remains uncommon [10] [11] . Similarly the study by Memish et al. of CAP in the Middle East and North Africa showed that Streptococcus pneumoniae is the most common bacterial pathogen [15] . In one study, influenza virus was responsible for up to (53%) of the cases of CAP and Staphylococcus aureus was an important pathogen in patients with diabetes (23%) compared to (10%) in those without diabetes [15] .
No data was found in the literature about the etiology (29.3%) , and levofloxacin (0.5%). The aim of this surveillance study was to obtain data about the epidemiologic characteristics, serotypes, and antibiotic susceptibilities of Streptococcus pneumoniae isolates causing invasive disease in Lebanon [17] .
In a study by Daoud et al. [18] , a total of 121 strains of Streptococcus pneumoniae were isolated between 2005 and 2009 from two university hospitals in Beirut. Out of 121 isolates, 58 were susceptible to penicillin, 61 were intermediate, and 2 were fully resistant to this antibiotic. Amoxicillin-clavulanic acid and cefpodoxime showed 100% activity on all tested isolates. Fifty-four percent of isolates were penicillin non-susceptible with MIC ranging between 0.004 and 2 mg/L. The isolates showed percentages of non-susceptibility to clarithromycin varying from 25.7%-41.4%, and ofloxacin susceptibility was around 94%. Other investigators found similar results where erythromycin resistance reached up to (30%) in 2010 Streptococcus pneumoniae isolates [3] .
Naba et al. have described the emergence of three isolated strains of levofloxacin resistant Streptococcus pneumoniae [19] . In a study by Kanj et al. , looking at the antibiogram of respiratory pathogens collected between 2003 and 2004 in a tertiary care center in Lebanon, resistance in Streptococcus pneumoniae isolates using MIC > 8 mg/L was not detected [20] . However, when using the MIC between 0.02 mg/L and 2 mg/L, resistance was detected in 30% of the strains, with Haemophilus influenza strains sensitivity to amoxicillin/clavulanic acid reaching (95%) active against and (100%) active against Moraxella strains. No data is available from Lebanon evaluating susceptibility patterns of strains of Klebsiella pneumoniae that come only from the community and cause CAP. All published Lebanese data about Klebsiella pneumoniae come from pooled data that include nosocomial and communityacquired strains causing collectively either pneumonia, intra-abdominal, postsurgical or urinary tract infections [3] .
Diagnostic testing I Chest Radiograph
A chest radiograph is required for the routine evaluation of patients who are likely to have pneumonia in order to establish a proper diagnosis and to aid in differentiating CAP from other common causes of cough and fever, such as acute bronchitis (level III evidence) [9] [10] .
The chest radiograph does not need to be repeated prior to hospital discharge in those who have made a satisfactory clinical recovery from CAP (level I evidence). For patients who are hospitalized for suspected pneumonia but who have negative chest radiography findings, it may be reasonable to treat their condition presumptively with antibiotics and repeat the imaging in 24-48 hours [9] . A chest radiograph should be arranged after about 6 weeks for all those patients who have persistence of symptoms or physical signs or who are at higher risk of underlying malignancy [21] .
I Other tests
For outpatients: No tests are recommended other than the chest X-ray (CXR) and C-reactive protein (CRP). Routine diagnostic tests for an etiologic diagnosis are optional (level III evidence) [9] .
For inpatients, the following tests are required: complete blood count with differential (CBCD), CRP, blood cultures, sputum cultures, Gram staining for both, urinary antigen tests for Legionella pneumophila and Streptococcus pneumoniae, and expectorated sputum samples collected for culture. For intubated patients, endotracheal aspirate sample should be obtained (level II evidence) [9] . Yet, these recommendations are considered of level III evidence in the ESCMID guidelines [10] [11] .
Site of care
Almost all decisions about investigation and management of CAP, including the selection of site of care, depend on the initial assessment of the severity of the illness. The selection of the site of care (outpatient, or inpatient in a ward, or in an intensive care unit) is the most important clinical decision in managing patients with CAP. So the choice of antimicrobial therapy, the intensity of medical observation, and the need for other resources depend largely on the selected site of care [9] [10] [11] . CURB-65 [22] (Table IV) and/or PSI (Pulmonary severity index) scores [23] (Tables II & III) can be used for the decision of inpatient or outpatient management (Strong recommendation; level I evidence), and objective criteria should always be supplemented by subjective factors like the availability of support at home and the ability to take oral medication (Strong recommendation; level II evidence) [9] [10] [11] .
Inpatients with a PSI of classes IV and V (> 90), and/or a CURB-65 of ≥ 2, hospitalization should be seriously considered (Moderate recommendation; level III evidence) [9] [10] [11] .
If admission is not indicated as per risk assessment and where home care is planned, patients are advised on self-care such as using analgesia, staying well hydrated and on quitting smoking provided that they receive the necessary support and treatment with suitable antibiotics [10] [11] 24] .
Direct admission to an intensive care unit is recommended for patients presenting with CURB ≥ 3, or with PSI > 90, or with CAP with one major or three of the minor criteria for severe CAP (level II evidence) [9] (Table V) . (Table VI) Outpatients (with or without comorbidities)
• In both cases, same management is followed because of high macrolide resistance in Streptococcus pneumoniae [9, 17, 20, 25] . A ß-lactam plus a macrolide is preferred (strong recommendation; level I evidence).
• For the ß-lactam, a high-dose amoxicillin (1g 3 times daily) or amoxicillin-clavulanate (1.2 g twice daily) is preferred; alternatives would include ceftriaxone (2 g IM or IV once daily), cefpodoxime (200 mg twice per day) or cefuroxime (500 mg twice per day) (level I evidence).
• As for macrolides, azithromycin (500 mg daily for 3 days) or clarithromycin (500 mg twice per day or 1 g once daily for the extended release formulation) can be used.
• Doxycycline can be used as an alternative to the macrolides (100 mg twice per day).
• Monotherapy with a macrolide or doxycycline is not recommended because of the high incidence of Streptococcus pneumoniae resistance in Lebanon [17, 20] .
• In order to decrease the effect of collateral damage [26] [27] , fluoroquinolones are to be used only as an alternative to the above regimen [9, 10-11]: levofloxacin (750 mg once daily), gemifloxacin (320 mg once daily), or moxifloxacin (400 mg once daily).
Inpatients
¢ With advanced chronic obstructive pulmonary disease (COPD), and/or on home oxygen, and/or on steroids, presenting with CAP, levofloxacin is the preferred fluoroquinolone regimen to cover for possible Pseudomonas infection pending culture results.
¢ Admitted to non-ICU ward
A ß-lactam (amino-penicillin/clavulanic acid) + a macrolide (level I evidence) [9] . The ß-lactam can be [10] :
-Ampicillin 4 g/day is preferred (level I evidence).
-A 3 rd generation cephalosporin including cefotaxime (1-2 g every 8 hours), ceftriaxone (2 g once daily), or ceftizoxime (1-2 g every 8 hours). Doses of macrolides are as above. Doxycycline can be used as an alternative to macrolides [9] [10] . Respiratory fluoroquinolones are used only as an alternative in case of allergy or intolerance in order to decrease its collateral damage nationwide [26] [27] .
¢ Inpatients admitted to an ICU
PATIENT STRATIFICATION It is necessary to assess the risk of Pseudomonas aeruginosa infection in patients admitted to an ICU in order to promptly choose the proper treatment regimen (level III evidence) [10] . rd generation cephalosporin + respiratory fluoroquinolones e.g. moxifloxacin or levofloxacin) is recommended (level I evidence). Doses are same as above [9] .
• It is preferable to add a respiratory fluoroquinolone or vancomycin in septic patients because of the 17% prevalence of penicillin resistance with MIC > 8 mg/L among the Streptococcus pneumoniae isolates in Lebanon (level I evidence) [9, 17] .
• For penicillin-allergic patients, a respiratory fluoroquinolone is recommended + aztreonam (level I evidence) [9] .
ICU patient at risk for Pseudomonas infection
• An antipneumococcal antipseudomonal ß-lactam (piperacillin/tazobactam 4.5 g every 6 hours or cefepime (2 g every 8 hours ) or meropenem (1 g every 8 hours) or imipenem (1 g every 8 hours) plus either ciprofloxacin (400 mg IV every 12 hours) or levofloxacin (750 mg once daily) (level III evidence) [9] .
• OR the above ß-lactams + an aminoglycoside (amikacin 20 mg/kg/day) and a macrolide (azithromycin or clarithromycin) (level III evidence) [9] . N.B. For CAP with MRSA, add vancomycin or linezolid (level III evidence) [9] .
Antiviral therapy
Viral pneumonia can be due to influenza virus, para influenza virus, RSV, adenovirus, metapneumo virus, the SARS agent, Hantavirus or Middle East Respiratory Syndrome Corona virus. Antiviral therapy is of proven value in influenza pneumonia, varicella zoster pneumonia or herpes zoster pneumonia and not in all other viral etiologies. For all patients with viral pneumonias, a high clinical suspicion of bacterial superinfection should be maintained. Parenteral acyclovir is indicated for treatment of varicella-zoster virus infection or herpes simplex virus pneumonia [9] .
• The empirical use of antiviral agents in patients suspected of suffering from influenza is usually not recommended. Antiviral treatment should be considered only: -In high-risk patients who have typical influenza symptoms (fever, muscle ache, general malaise and respiratory tract infection) for 2 days. -During a known influenza epidemic.
• Early treatment (within 48 hours of the onset of symptoms) is recommended for influenza A (level I evidence) [9] .
• The use of oseltamivir and zanamivir is not recommended for patients with influenza with symptoms of more than 48 hours (level I evidence), but these drugs may be used to reduce viral shedding in hospitalized patients or for influenza pneumonia treatment (level III evidence) [9] .
• The treatment is oseltamivir (75 mg twice per day or 150 mg twice per day) in severe illness or zanamivir (10 mg twice daily for 5 days). The 10 mg dose is provided by 2 inhalations (one 5-mg blister per inhalation). Zanamivir is not recommended for the treatment of patients with underlying airways disease [9] .
Treatment timing issues
• Treatment of CAP should be started as soon as the diagnosis is made (level I evidence) [10] .
• In hospitalized patients, the first dose should be given in Emergency Department (level I evidence) [9] and in septic patients antibiotic treatment should not be delayed more than one hour after diagnosis (level I evidence) [10] .
• Treatment duration ranges between 5 to 8 days and can be extended in case of complications like empyema, abcess formation or if the patient is immunocompromised (level I evidence) [9] .
• Treatment can be switched from IV to PO when the patient is stable and after resolution of the most prominent symptoms (level III evidence) [10] .
Additional therapies
• Low molecular weight heparin is indicated in patients with acute respiratory failure.
• The use of noninvasive ventilation may be considered particularly in patients with COPD [9] .
• Steroids have no place in the treatment of CAP in the absence of COPD, unless septic shock is present [9] .
Additional Recommendations
It is essential to advise patients to:
• Use paracetamol or ibuprofen as required thus reducing temperature and symptoms of malaise.
• To rest and drink a sufficient amount of fluids to prevent dehydration.
• Observe the frequency and color of urine. Fluid intake should be increased if urine is passed infrequently and is dark in color.
• Avoid cough suppressant medicines.
• Quit smoking. Physician might need to offer support and guidance for smoking cessation [9] [10] [11] .
PREVENTION OF CAP
Influenza
Inactivated influenza vaccine is recommended for persons aged > 6 months of age, as recommended by the Advisory Committee on Immunization Practices (ACIP), and the Center for Disease Control and Prevention (level I evidence) [28] . Healthcare workers in inpatient, outpatient, or longterm care facilities should receive annual anti-influenza immunization [28] .
Pneumococci
• Pneumococcal polysaccharide vaccine (23-valent polysaccharide vaccine) (Pneumovax23 ® , PPSV23) is recommended for persons aged ≥ 65 years and those with selected high-risk concurrent diseases, according to ACIP guidelines (level I evidence). [29] . It is worth mentioning that (Prevnar13 ® , PCV13) has been approved by the FDA in Decem-ber 2011 for use in adults aged 50 or above [28] [29] .
• A CDC advisory committee on immunization practices recommended lately that adults with immunocompromised conditions should receive the 13-valent pneumococcal conjugate vaccine followed 8 weeks later with the 23-serotype polysaccharide vaccine [29] .
Smoking cessation should be a goal in general and particularly for hospitalized patients with CAP [9] [10] [11] .
Respiratory etiquette: Hand hygiene and cough etiquette should be taught in schools and well advertised to become integrated social habits.
COMPARISON TO REGIONAL GUIDELINES
These are the first CAP guidelines in the MENA (Middle East, North Africa) region; however, Saudi Arabia CAP Guidelines Working Group has put the Saudi CAP guidelines in 2002 [15] that were reviewed and updated by the Gulf Cooperation Council in 2007 [30] . Our guidelines follow the same subdivisions as the Saudi and GCC guidelines, but the empiric treatment recommendations do differ.
In our guidelines, we recommend fluoroquinolones to be used in ICU patients with severe pneumonia like in the Saudi and GCC guidelines [30] . however, outside the ICU, we have put fluoroquinolones only as an alternative not a primary choice, in order to decrease collateral damage and hopefully curb antibiotic resistance trends.
On the other hand, the Saudi and GCC guidelines [30] recommend macrolide monotherapy in outpatients with no comorbidities; yet due to macrolide resistance in the Lebanese microbiology data, we recommend adding a ß-lactam antibiotic to macrolides in this category of patients. Our recommendation is based on that of the IDSA guidelines, which clearly state that if macrolide resistance is ≥ 30% in a community, macrolide monotherapy should be avoided (level I evidence) [9] . CONCLUSION The LSID members consider these guidelines as a first step in a long journey that should be followed immediately by the initiation of a national antimicrobial resistance surveillance system. This system will monitor resistance patterns in target strains both in community and health care settings which will allow us to perform a periodic review of the guidelines and update them according to new research and official national trends of antimicrobial resistance.
